iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.62 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-03-13
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.62, a 60.10% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $4.06.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.62, a 60.96% decline from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.15, a 38.15% decline from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2021 was $6.71.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.62 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $1.62 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $1.62 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $1.62 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $4.15 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $4.20 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $4.31 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $4.06 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $6.71 10-K/A · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |